|
| Tuesday, 20 September 2022, 23:50 HKT/SGT | |
| |
|
|
|
Gaithersburg, MD, USA and Suzhou BioBay, China, Sept 20, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead(TM) platform and programs, at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference. The conference will take place on September 21 and 22, 2022 with workshops on September 20, 2022 at Copthorne Tara Hotel, London, UK.
Presentation Details
Presentation Title: Delivery of Novel siRNA Constructs for Treating Cancer
Presenter: Dr. David Evans, Chief Scientific Officer, Sirnaomics
Time/Date: 15:20 GMT on Wednesday, September 21, 2022
Presentation Topics:
-- Creating novel siRNA constructs for cancer treatment
-- Introduction to Sirnaomics' polypeptide nanoparticle delivery system (PNP-IT)
-- Introduction to STP705, Sirnaomics' lead oncology siRNA therapeutic targeting TGF-beta1/COX-2
-- Discussion of novel siRNA therapeutics targeting other oncology indications
Presentation Title: GalAhead(TM) Therapeutic Platform and Programs
Presenter: Dr. Jack Wei, Senior Director, Sirnaomics
Time/Date: 16:30 GMT on Thursday, September 22, 2022
Presentation Topics:
-- Introduction to GalAhead(TM), Sirnaomics' GalNAc-RNAi therapeutic platform
-- Miniaturized RNAi (mxRNA) as a key technological component of the platform
-- Validation of technology in vivo and in vitro
-- Progress report on GalAhead(TM)-based programs
For more information about Sirnaomics' presentation, please visit the event website at https://www.smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery.
About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.
CONTACT:
Investor Relations:
Nigel Yip, MBA
Chief Financial Officer, China, Sirnaomics
Email: NigelYip@sirnaomics.com
US Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com
Asia Media Contact:
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com
Topic: Press release summary
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Casa Minerals Announces 2026 Aggressive Exploration Plans for Congress Gold Mine and Arsenault Projects
Feb 26, 2026 21:59 HKT/SGT
|
|
|
Mitomo Semicon Engineering to Change Company Name
Thursday, February 26, 2026 9:00:00 PM
|
|
|
Truecaller Partners with AnyMind Group to Expand Direct Sales Footprint Across MENA and Southeast Asia
Feb 26, 2026 20:20 HKT/SGT
|
|
|
U.S. Polo Assn. Returns as Official Apparel and Jersey Sponsor of the 2026 Dubai Polo Gold Cup for Third Consecutive Year
Feb 26, 2026 20:00 HKT/SGT
|
|
|
Truecaller Partners with AnyMind Group to Expand Direct Sales Footprint Across MENA and Southeast Asia
Feb 26, 2026 19:50 HKT/SGT
|
|
|
Truecaller Partners with AnyMind Group to Expand Direct Sales Footprint Across MENA and Southeast Asia
Feb 26, 2026 18:50 HKT/SGT
|
|
|
The University of Tokyo, NTT, and NEC demonstrate real-time augmented reality assistance made possible by integrating three newly proposed technologies on a 6G/IOWN platform to realize the widespread use of AI agents supporting safety and security
Thursday, February 26, 2026 6:01:00 PM
|
|
|
NEC and Nokia to Expand Eletrone's Optical Fiber Network in Brazil by 50%
Thursday, February 26, 2026 5:51:00 PM
|
|
|
Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM
Thursday, February 26, 2026 2:27:00 PM
|
|
|
Champion REIT Delivers Resilient Performance, Proactive Tenant Mix Optimisation Drives Sustainable Development
Feb 26, 2026 14:23 HKT/SGT
|
|
|
|
|
More Press release >> |
|
 |
|
 |
|
